Adding Palbociclib Delays Progression in HR-Positive Breast Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor–positive HER2-negative breast cancer.

In this video, Nicholas C. Turner, MD, of Royal Marsden Hospital and the Cancer Research Institute in London, discusses the results of the PALOMA3 trial, which tested fulvestrant and palbociclib in metastatic, hormone receptor (HR)-positive HER2-negative breast cancer.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
Related Content
Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Jordyn Sava
December 12th 2024
Article

Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

Kristi Rosa
December 12th 2024
Article

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Active Monitoring Noninferior to Standard Surgery, RT in Low-risk DCIS

Gina Mauro
December 12th 2024
Article

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Real-World Data Show No OS Difference Among CDK4/6 Inhibitor Combos in HR+/HER2– MBC

Real-World Data Show No OS Difference Among CDK4/6 Inhibitor Combos in HR+/HER2– MBC

Morgan Bayer
December 12th 2024
Article

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.